Novartis said on Thursday that its Cosentyx drug had failed in a late-stage trial on adults with giant cell arteritis (GCA), ...

"Novartis’ Cosentyx shows no benefit in Phase III GCA trial" was originally created and published by Clinical Trials Arena, a ...

Novartis is falling farther behind AbbVie, which expanded its JAK inhibitor Rinvoq into giant cell arteritis in April.

Novartis’s Cosentyx failed to beat a placebo in a Phase 3 clinical trial in giant cell arteritis. The antibody drug was being developed as an alternative to Roche and AbbVie drugs whose approved ...

Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial ...

Novartis' blockbuster immunology drug Cosentyx has disappointed in a phase 3 trial involving patients with giant cell ...

Medicine company Novartis (NVS) said on Thursday that a late-stage trial evaluating its drug Cosentyx in adults with newly ...

“While the phase 3 results of GCAptAIN did not replicate the positive outcomes observed in the phase 2 trial, we remain committed to continuing to drive scientific progress and deepening the ...

Cosentyx can cause certain side effects, some of which are more common than others. These side effects may be temporary, lasting a few days or weeks.

COSENTYX may cause serious side effects, including: Serious allergic reactions. Serious allergic reactions can occur. Get emergency medical help right away if you get any of the following symptoms ...

A late-stage trial testing Novartis’ Cosentyx in individuals with giant cell arteritis failed to meet its primary endpoint. The phase 3 study tested Cosentyx alongside a 26-week steroid taper and ...

Novartis’ Cosentyx (secukinumab) has failed to show any benefit in the Phase III study in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the GCAptAIN trial (NCT04930094 ...